MOTION

No. 123

Urging government to increase access to ovarian cancer drugs

Michele Beaton gives notice that tomorrow she will move, seconded by Karla Bernard, the following Motion:

WHEREAS ovarian cancer is the most fatal women's cancer in Canada;

AND WHEREAS everyone who is born with ovaries has some risk for this disease;

AND WHEREAS ovarian cancer is notoriously difficult to detect and there is no reliable screening test for this disease;

AND WHEREAS approximately 3,000 Canadian women are diagnosed with ovarian cancer each year with more than half of those diagnosed dying within five years of their diagnosis;

AND WHEREAS people affected by ovarian cancer deserve to live fuller, better and longer lives;

AND WHEREAS the most promising treatment advance in recent years is the success of poly (ADP-ribose) polymerase (PARP) inhibitors like Lynparza and Zejula;

AND WHEREAS PARP inhibitors like Lynparza and Zejula are described as "game-changers" by gynecologists and medical oncologists and researchers;

AND WHEREAS every Canadian province, except for PEI, lists these drugs on their formulary, and covers the cost of these medications;

THEREFORE BE IT RESOLVED that the Legislative Assembly of Prince Edward Island urge government to increase the funding to the PEI Drug Formulary so drugs such as Lynparza and Zejula can be considered.

Signed: Michele Beaton

Signed: Karla Bernard

Date: November 1, 2022